寧德時代(300750.SZ)折讓23%配股 募資450億人幣
據外電報道,寧德時代(300750.SZ)已啟動67億美元(約450億元人民幣)配股,該規模在年初至今全球股權資本市場(ECM)交易中排名第二,僅次於LG新能源今年1月在韓國上市募資99.4億美元。
據悉,在定向增發方案中,寧德時代擬向不超過35名投資者募集最多450億元人幣,每股下限定價339.67元人幣,較該股昨日收市價443.03元人幣折讓23.33%,每名投資者至少認購12億元人幣,定增方案設6個月禁售期。
中信建投(06066.HK)為此項交易的保薦人,高盛高華、中金(03908.HK)、瑞銀、華福證券為聯席賬簿管理人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.